Mizuho Securities analyst Salim Syed maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of $207.00.
Japan’s leading financial services group is likely to sign a definite agreement in a month to buy around 80% stake in Avendus ...
Genpact (NYSE:G – Get Free Report) had its target price hoisted by analysts at Mizuho from $45.00 to $55.00 in a research ...
Mizuho Financial Group Inc.’s profit rose in the third quarter, propelling it past its record annual earnings projection ...
Lennox International downgraded at Mizuho, driven by lower 2025 and 2026 estimates and broader HVAC peer market de-rating in ...
To achieve carbon neutrality in an increasingly uncertain world, Japanese companies should focus on innovations for ...
Mizuho Securities analyst Gregg Moskowitz maintained a Buy rating on Salesforce (CRM – Research Report) today and set a price target of ...
Mizuho has downgraded STAAR Surgical (STAA) to neutral from outperform, citing a slowdown in sales of its Implantable ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results